Emerging anti-inflammatory drugs for atherosclerosis

Biomarkers and Sustainable Innovation in Cardiovascular Drug Development: Lessons from Near and Far Afield

(2013) Russell M. Medford et al.   Current Atherosclerosis Reports

A Novel C^|^#8211;C Chemokine Receptor 2 Antagonist Prevents Progression of Albuminuria and Atherosclerosis in Mouse Models

(2012) Masayuki Okamoto et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Effects of Interleukin-1β Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen

(2012) Paul M Ridker et al.   CIRCULATION

Phospholipase A2 enzymes and the risk of atherosclerosis

(2012) R. S. Rosenson et al.   EUROPEAN HEART JOURNAL

Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2

(2012) Robert S. Rosenson et al.   JOURNAL OF LIPID RESEARCH

Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis

(2012) Nicolino Ruperto et al.   NEW ENGLAND JOURNAL OF MEDICINE

Study design and rationale for the Stabilization of pLaques usIng Darapladib—Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome

(2011) Michelle L. O'Donoghue et al.   AMERICAN HEART JOURNAL

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

(2011) Paul M Ridker et al.   AMERICAN HEART JOURNAL

Effect of CC Chemokine Receptor 2 CCR2 Blockade on Serum C-Reactive Protein in Individuals at Atherosclerotic Risk and With a Single Nucleotide Polymorphism of the Monocyte Chemoattractant Protein-1 Promoter Region

(2011) Jim Gilbert et al.   AMERICAN JOURNAL OF CARDIOLOGY

AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update

(2011) Sidney C. Smith et al.   CIRCULATION

Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials

(2011) E. Braunwald   EUROPEAN HEART JOURNAL

15 Investigation of IL-1 inhibition in patients presenting with non-ST elevation myocardial infarction acute coronary syndromes (the MRC ILA Heart Study)

(2011) A. C. Morton et al.   HEART

Anti-inflammatory therapeutics for the treatment of atherosclerosis

(2011) Israel F. Charo et al.   NATURE REVIEWS DRUG DISCOVERY

Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease

(2010) Harvey White et al.   AMERICAN HEART JOURNAL

Functional Assessment of HDL: Moving Beyond Static Measures for Risk Assessment

(2010) Robert S. Rosenson   CARDIOVASCULAR DRUGS AND THERAPY

Pleiotropic Effects of Statins

(2010) Qian Zhou et al.   CIRCULATION JOURNAL

Lp-PLA2 and risk of atherosclerotic vascular disease

(2010) Robert S Rosenson   LANCET

Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

(2010)   LANCET

Future Role for Selective Phospholipase A2 Inhibitors in the Prevention of Atherosclerotic Cardiovascular Disease

(2009) Robert S. Rosenson   CARDIOVASCULAR DRUGS AND THERAPY

Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans

(2009) Ethan J. Anderson et al.   JOURNAL OF CLINICAL INVESTIGATION

Inflammation in Atherosclerosis

(2009) Peter Libby et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)

(2009) PAUL M. RIDKER   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Chemokines in Atherosclerosis

(2008) Alma Zernecke et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis

(2008) Kenneth G. Saag et al.   ARTHRITIS AND RHEUMATISM

Biology of Secretory Phospholipase A2

(2008) Boris B. Boyanovsky et al.   CARDIOVASCULAR DRUGS AND THERAPY

Biology of Platelet-activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A2)

(2008) Diana M. Stafforini   CARDIOVASCULAR DRUGS AND THERAPY

Inflammation and Cardiovascular Disease

(2008) William F. Fearon et al.   CIRCULATION

Effects of the Direct Lipoprotein-Associated Phospholipase A 2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque

(2008) Patrick W. Serruys et al.   CIRCULATION

Common polymorphisms of ALOX5 and ALOX5AP and risk of coronary artery disease

(2008) Themistocles L. Assimes et al.   HUMAN GENETICS

Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial

(2008) Jean-Claude Tardif et al.   LANCET

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE